Systemic inflammation in suppressed HIV similar after switch to 3-drug ART

In adults with HIV maintaining viral suppression, switching from dolutegravir plus lamivudine (DTG/3TC) to bictegravir plus emtricitabine and tenofovir alafenamide (BIC/FTC/TAF) does not improve inflammatory or metabolic outcomes over 96 weeks,…